
Conference Coverage
about 12 hours ago
AI Use in Breast Cancer Care Requires Human Oversight: Amrita Basu, PhDabout 13 hours ago
T-DXd Delivers Strong Breast Cancer Outcomes Across GroupsLatest Content

New 9-Gene Classifier May More Accurately Predict Metastasis Across STS, Other Cancers

MRD-Guided Therapy Shows Promise as a Time-Limited Frontline Strategy for MCL

Study Identifies Key Predictors of Successful CD3+ Cell Apheresis for CAR T Manufacturing in DLBCL

Postmarket Drug Safety Timelines Largely Unchanged After FDA Amendments Act

Genome-Wide Analysis Uncovers Genetic Drivers of IPF and Its Overlap With COVID-19

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Research at the San Antonio Breast Cancer Conference highlights T-DXd's superior efficacy and safety in HER2+ metastatic breast cancer, especially among diverse populations.

Clinicians and health system leaders met in Cleveland, Ohio, on October 23, 2025, to share improvements to value-based care in diabetes and chronic kidney disease.

As value-based care mandates expand, a new survey highlights documentation burdens and burnout risks.

The RAISE program provides awareness and shares comprehensive solutions to address the multifaceted reasons for missing and incomplete data across the real-world data continuum.

A low-protein diet is essential for managing chronic kidney disease (CKD), potentially slowing progression and improving health outcomes while tailoring to individual needs.

In analyzing 2025 Transparency in Coverage (TIC) files from national insurers, the authors found vast payer-level differences; overall, physician/outpatient data were more complete, and hospital inpatient data were less complete.

A groundbreaking in vivo CAR T-cell therapy shows promise for treating multiple myeloma, potentially revolutionizing cancer care with quicker, safer treatments.

School reopenings after COVID-19 closures significantly improved children's mental health, reducing diagnoses of depression, anxiety, and ADHD.

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

New research highlights INCA033989's potential in treating mutCALR-driven essential thrombocythemia and myelofibrosis, achieving significant molecular responses.



























































